Summary: Lead managers: Bell Potter and Morgans Cornerstone investors: Ellerston, Washington H. Soul Pattinson and Australian Unity Valuation: apparently attractive, comparing to other listed ASX businesses active in this space Stage of product development: phase three of clinical trials in 2022 (again, among a few only on ASX that reached that stage)
I am in with a spread allocation. The backers, valuation, product and the lead manager (Morgans) drew my interest.
